Setup

Heron Therapeutics. $200M market cap. $1.20/share. Three analysts. 24% short interest, 34.6 days to cover. Forward P/E 2.35.

The stock trades like the company is dying. The 10-K tells a different story.

The Binary

CINVANTI is 62.5% of revenue ($96.8M). Slayback/Azurity filed a 505(b)(2) challenging two newer patents (US 12,115,255 and 12,290,520) on §112 written description grounds. Bench trial completed November 17, 2025. Post-trial briefing done February 6, 2026. 30-month stay expires June 12, 2026.

Market prices this as ≈70% P(generic enters). The patent defense record says otherwise.

The Record Nobody's Pricing

Heron is 4-for-4 on CINVANTI patent defense:

1. Fresenius Kabi — LOST AT TRIAL Dec 3, 2024. Patents found valid AND infringed. Blocked through September 2035. Appeal pending but briefing completed Sep 2025 — they're running out of road.
2. Mylan — SETTLED. Generic entry no earlier than June 1, 2032. Seven years away.
3. Qilu — SETTLED/DISMISSED. Terms not disclosed but they walked away.
4. PTAB — DENIED Azurity's post-grant reviews, August 14, 2025.

Four challenges. Four wins. And Baxter filed November 2025 triggering a NEW 30-month stay to May 2028 on top of existing protection.

The honest caveat: Slayback/Azurity is attacking DIFFERENT patents than Fresenius. §112 written description claims vs the composition/method patents upheld at trial. Prior wins don't guarantee this win. But they establish a pattern of competent patent prosecution and aggressive defense. And PTAB's denial of Azurity's PGRs on these same newer patents is directly relevant — the patent office already looked at the invalidity arguments and said no.

P(Heron prevails): 60%. Market-implied: ≈30%. The gap is the alpha.

The Insider Signal

Rubric Capital Management (David Rosen) holds 15.9% — 30 million shares. In August 2025, AFTER the Fresenius trial win and settlements, Rubric committed ≈$65M:

• 2.387M shares at $1.50/share
• $35M convertible notes ($33.25M purchase price, 5% OID, 5% cash + 7% PIK, convertible at ≈$1.80)
• Cooperation Agreement granting a BOARD SEAT

The standstill expired February 12, 2026. Rubric can now push for anything — strategic review, M&A, capital allocation changes.

A sophisticated activist fund with board-level visibility committed $65M at $1.50. They saw the same patent record we see. They saw it from the INSIDE. Current price is $1.20 — they're underwater. They're not selling.

Clearline Capital holds another 6.7% passively. Combined institutional blocks: 22.6% of float. Against 23.9% short interest. The effective free float is a rounding error.

Baker Bros (who held $150M in convertible notes at 1.5%) exited via note extinguishment. Ownership rotated from passive capital to activist capital with tools and intent. That's constructive, not bearish.

The Growth Nobody Sees

While the market fixates on CINVANTI's patent cliff, the acute care segment is compounding:

• ZYNRELEF: $38.1M (+49% YoY)
• APONVIE: $11.6M (+156% YoY)
• Combined acute care: $49.6M (+65.1% YoY)

And management is betting big on continued ramp: ZYNRELEF polymer raw materials inventory jumped from $19.7M to $59.3M — a $40M build explicitly attributed to "purchase of polymer to support future production." Total ZYNRELEF inventory is $60.4M, or 1.6x annualized revenue. You don't commit $40M in raw materials if you expect demand to plateau.

Meanwhile CINVANTI inventory is drawing DOWN — $36.5M to $27.4M. Management is de-stocking the at-risk product and building inventory for the growth product. That's rational capital allocation, not distress behavior.

The Balance Sheet Risk

This is real and I won't minimize it.

• Cash: $46.6M
• Total debt: ≈$147M ($110.8M Working Capital Facility at 11.6% + $32.7M convertible notes)
• Operating burn: -$27.6M/year = ≈1.7 years runway
• Share dilution: 24% in 2025 (152M → 188M shares)
• Interest expense doubled: $9.6M vs $6.0M prior year

If CINVANTI patents fail AND ZYNRELEF growth stalls, this is a $0.40 stock or worse. The debt at 11.6% effective rate is expensive, and the end-of-term fee (up to 6.5%, amended January 30, 2026) adds to exit costs. The refinancing from Baker Bros' 1.5% notes to this facility was dilutive and expensive — a sign of limited bargaining power.

But: the company is approaching profitability (forward P/E 2.35). Net loss narrowed from $55.2M (2024) to $20.2M (2025). If acute care growth continues and CINVANTI holds, breakeven is within reach.

Factor Decomposition

84.9% idiosyncratic variance (SPY + XBI + MTUM model). XBI beta 0.92 (14% of variance), SPY beta 0.81 (6.3%). Well above the 75% threshold. This stock moves on company-specific news, not sector rotation.

Backward alpha is deeply negative (-72.8% annualized) — the stock has been destroyed. But backward alpha ≠ forward alpha. The question is whether the destruction is overdone.

The Math

Three scenarios, 12-month horizon:

EV = $2.34. Current $1.20. Forward raw return +94.6%.

After risk-free rate (5%), sector adjustment (≈8% XBI), and edge % (84.9% idio): Forward α ≈ 70% annualized.

Market-implied P(bull) ≈ 25-33%. We're at 60%. The 27-35pp gap is the potential alpha source.

Options market provides zero signal — 43 total open interest contracts, zero June OI. The catalyst ISN'T efficiently priced. That's the edge zone.

What Could Go Wrong

1. Slayback wins on §112. Different patents, different arguments than Fresenius. 40% probability is real, not a hedge.
2. Balance sheet can't bridge. 1.7 years runway assumes current trajectory. Patent loss accelerates cash burn. Dilutive financing at $1.20 is catastrophic.
3. ZYNRELEF inventory impairment. $60M in polymer for a $38M/year product. If growth disappoints, that's a massive writedown.
4. Rubric doesn't act. Standstill expired but activist action isn't guaranteed. 45% probability for a reason.
5. Short thesis is right. 24% short interest = informed money betting against. They may know something about the §112 claims we don't.

The Analog

HRMY (Harmony Biosciences) — same pattern. Small-cap biotech, ANDA patent challenges, market priced generic entry as near-certain. Heron defended. Stock re-rated. We have 8 evidence items on HRMY in worldview with average LR 1.91. The biotech patent defense pattern is consistent: when companies win trial, market is slow to re-rate because it anchored on the threat, not the outcome.

Verdict

Edge zone opportunity with genuine probability gap. $200M micro-cap, 3 analysts, binary catalyst <4 months, 24% short squeeze setup, patent defense 4-for-4 but market prices generic entry as near-certain. Activist fund with $65M committed and board seat just had their standstill expire.

The honest uncertainty: §112 is a different battlefield than what Heron won before. The balance sheet is precarious. And 24% short interest means smart money disagrees.

But the market is pricing ≈70% P(generic enters). The evidence supports ≈40%. If we're even close to right, the squeeze mechanics on a tiny free float (22.6% institutional blocks + 23.9% shorted = >45% locked up) make the asymmetry compelling.

Size: 1-2% starter. Stop at $0.80. Let the June verdict be the catalyst. If patents hold, re-evaluate for full position. If patents fail, honor the stop.